{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:15:53Z","timestamp":1777518953262,"version":"3.51.4"},"reference-count":47,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,3,1]]},"abstract":"<jats:p> PURPOSE: To evaluate the efficacy of rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) induction therapy in patients with newly diagnosed mantle-cell lymphoma (MCL). <\/jats:p><jats:p> PATIENTS AND METHODS: From March 1997 to May 1999, 40 previously untreated patients with stage II through IV MCL were treated with six cycles of rituximab and CHOP chemotherapy in a phase II trial. Pretreatment and interval peripheral-blood (PB) and bone marrow (BM) specimens were also analyzed by polymerase chain reaction (PCR) for tumor-specific BCL-1\/immunoglobulin H (IgH) translocations and clonal IgH rearrangements. Study end points included clinical and molecular response rates and long-term progression-free survival (PFS). <\/jats:p><jats:p> RESULTS: Forty-eight percent of patients achieved a complete response (CR)\/CR unconfirmed (CRu), and 48% of patients obtained a partial response (PR). However, 28 of the 40 patients have already relapsed or developed progressive disease with a median PFS of 16.6 months. Twenty-five patients had PCR-detectable BCL-1\/IgH or clonal IgH products in PB or BM at diagnosis. Nine of the 25 informative patients had no evidence of PCR-detectable disease in PB or BM after rituximab and CHOP therapy. However, patients who achieved molecular remissions in PB or BM had PFS similar to patients without molecular remissions (16.5 v 18.8 months, P = .51). <\/jats:p><jats:p> CONCLUSION: Favorable clinical and molecular response rates associated with rituximab and CHOP chemotherapy do not translate into prolonged PFS in MCL. Nevertheless, rituximab and combination chemotherapy may transiently clear PB or BM of detectable tumor cells, prompting additional consideration of antibody-based in vivo purging in subsequent clinical trials. <\/jats:p>","DOI":"10.1200\/jco.2002.20.5.1288","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T08:51:36Z","timestamp":1487926296000},"page":"1288-1294","source":"Crossref","is-referenced-by-count":604,"title":["Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival"],"prefix":"10.1200","volume":"20","author":[{"given":"Orion M.","family":"Howard","sequence":"first","affiliation":[{"name":"From the Departments of Adult Oncology, Biostatistics, and Radiology, Dana-Farber Cancer Institute, and Division of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[{"name":"From the Departments of Adult Oncology, Biostatistics, and Radiology, Dana-Farber Cancer Institute, and Division of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[{"name":"From the Departments of Adult Oncology, Biostatistics, and Radiology, Dana-Farber Cancer Institute, and Division of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Grossbard","sequence":"additional","affiliation":[{"name":"From the Departments of Adult Oncology, Biostatistics, and Radiology, Dana-Farber Cancer Institute, and Division of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Poor","sequence":"additional","affiliation":[{"name":"From the Departments of Adult Oncology, Biostatistics, and Radiology, Dana-Farber Cancer Institute, and Division of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milos J.","family":"Janicek","sequence":"additional","affiliation":[{"name":"From the Departments of Adult Oncology, Biostatistics, and Radiology, Dana-Farber Cancer Institute, and Division of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret A.","family":"Shipp","sequence":"additional","affiliation":[{"name":"From the Departments of Adult Oncology, Biostatistics, and Radiology, Dana-Farber Cancer Institute, and Division of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-103963","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.10.2829.2829"},{"key":"R2-103963","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1269"},{"key":"R3-103963","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"R4-103963","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059155"},{"key":"R5-103963","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2067"},{"key":"R6-103963","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"R7-103963","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10056-9"},{"key":"R8-103963","unstructured":"Bertini  M,   Rus  C,   Freilone  R,  et al:   Mantle cell lymphoma:  A retrospective study on 27 patients. Clinical features and natural history.   Haematologica 83:  312,1998-316,"},{"key":"R9-103963","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1922"},{"key":"R10-103963","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609067588"},{"key":"R11-103963","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199602000-00010"},{"key":"R12-103963","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00684.x"},{"key":"R13-103963","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199403000-00018"},{"key":"R14-103963","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401121"},{"key":"R15-103963","unstructured":"Callea  V,   Clo  V,   Morabito  F,  et al:   Retrospective analysis of mantle cell lymphoma:  Experience of the \u201cGruppo Italiano per lo Studio dei Linfomi\u201d (GISL).   Haematologica 83:  993,1998-997,"},{"key":"R16-103963","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900070505"},{"key":"R17-103963","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"R18-103963","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059154"},{"key":"R19-103963","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B"},{"key":"R20-103963","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4693273.x"},{"key":"R21-103963","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059156"},{"key":"R22-103963","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008278605751"},{"key":"R23-103963","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"R24-103963","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701400"},{"key":"R25-103963","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.10.4212"},{"key":"R26-103963","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.2.724"},{"key":"R27-103963","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701637"},{"key":"R28-103963","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.6.1424.bloodjournal6361424"},{"key":"R29-103963","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90276-3"},{"key":"R30-103963","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1995.tb00615.x"},{"key":"R31-103963","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/110.5.582"},{"key":"R32-103963","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/105.4.451"},{"key":"R33-103963","unstructured":"Kumar  S,   Green  G,   Teruya-Feldstein  J,  et al:   Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma.  Mod Pathol 9:  925,1996-929,"},{"key":"R34-103963","unstructured":"Dorfman  DM,   Pinkum  GS:   Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23.  Mod Pathol 7:  326,1994-31,"},{"key":"R35-103963","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"R36-103963","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"R37-103963","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/11.suppl_1.S117"},{"key":"R38-103963","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"R39-103963","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/112.4.524"},{"key":"R40-103963","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401172"},{"key":"R41-103963","unstructured":"Segal  G,   Maiese  R:   Mantle cell lymphoma:  Rapid polymerase chain reaction-based genotyping of a morphologically heterogeneous entity.   Arch Pathol Lab Med 120:  835,1996-841,"},{"key":"R42-103963","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/104.6.689"},{"key":"R43-103963","unstructured":"Deane  M,   McCarthy  K,   Wiedemann  L,  et al:   An improved method for detection of B-lymphoid clonality by polymerase chain reaction.  Leukemia 5:  726,1991-730,"},{"key":"R44-103963","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R46-103963","doi-asserted-by":"publisher","DOI":"10.1038\/339237a0"},{"key":"R47-103963","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.864"},{"key":"R48-103963","unstructured":"Buckstein  R,   Imrie  K,   Spaner  D,  et al:   Stem cell function and engraftment is not affected by \u201cin vivo purging\u201d with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin\u2019s lymphoma.  Semin Oncol 26:  115,1999-122,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.20.5.1288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:58:31Z","timestamp":1653515911000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.20.5.1288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,1]]},"references-count":47,"aliases":["10.1200\/jco.20.5.1288","10.1200\/jco.20.5.1288","10.1200\/jco.20.5.1288"],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,3,1]]}},"alternative-id":["10.1200\/JCO.2002.20.5.1288"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.20.5.1288","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,1]]}}}